Paul A. Frohna, M.D., Ph.D., PharmD, is a physician-scientist with expertise in all facets of drug development from the bench to bedside that has been applied to the development of novel small molecules, biologics, peptides, and cell therapies in immuno-oncology, immunology, hematology, and neurodegenerative diseases for over 20 years. Prior to Endeavor, he served as the Chief Medical & Scientific Officer of ImCheck Therapeutics where he was responsible for all research and discovery activities for the pipeline of butyrophilin-targeted mAbs, including multiple Phase I/II clinical trials in solid and hematologic malignancies with the γ9δ2 T cell activating mAb, ICT01. Previously, he served in senior development roles at Bioniz Therapeutics (CMO), Receptos (VP), and Genentech (Sr MD) where he designed and conducted over 50 Phase I-III clinical trials, with the successful associated regulatory filings (IND, CTA, BLA), including 4 approved drugs. Serves as an Independent Director for Accure Therapeutics (Barcelona, SP) since 2017 and on the Scientific Advisory Board of IAMA Therapeutics (Genoa, IT) since 2023. Dr. Frohna trained in internal medicine after graduating with an M.D. from Georgetown University, a Ph.D. in Pharmacology from PENN, and a Pharmacy Degree from the University of Texas at Austin.